表紙：胃がん治療市場の規模、シェア、動向分析レポート：治療タイプ別、疾患適応症別、投与経路別、薬物クラス別、流通チャネル別、地域別、セグメント別予測、2022年～2030年

市場調査レポート

商品コード

1122228

胃がん治療市場の規模、シェア、動向分析レポート：治療タイプ別、疾患適応症別、投与経路別、薬物クラス別、流通チャネル別、地域別、セグメント別予測、2022年～2030年

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

出版日: 2022年08月26日 | 発行: Grand View Research

| ページ情報: 英文 140 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

Unprintable PDF (Single User License)

USD 5,950 932,722円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。PDFの印刷もできません。

Printable PDF (5-User License)

USD 6,950 1,089,482円

レポートPDFを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

Printable PDF (Enterprise License)

USD 8,950 1,403,002円

レポートPDFの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

胃がん治療市場の成長・動向

Grand View Research, Inc.の新しいレポートによると、胃がん治療の世界市場規模は2030年までに112億米ドルに達し、2022年から2030年までCAGR12.9％で拡大すると予測されています。免疫療法や標的療法の取り込みが進んでいることに加え、新薬の上市が成長を後押しするとみられています。

Globocanによると、2020年の胃がん発生率は約110万人で、2030年には142万人に増加すると予想されています。この疾患の分子基盤に関する知識の開拓が進み、標的薬や免疫療法薬の開発・上市が進んでいます。ハーセプチンなどのHER-2標的薬は、2010年以降、市場で販売されています。また、VEGF標的モノクローナル抗体であるサイラムザという標的薬も2014年から販売されています。現在、胃がんの治療薬としてEGFRやPD-1標的薬や免疫療法が開発されています。

また、臨床パイプラインにある薬剤の承認とその後の上市も、胃がん治療市場を牽引することが期待されます。例えば、2021年3月にNMPAは、Eli LillyとInnovent BiologicsのPD-1阻害剤である医薬品Sintilimabを、胃または胃食道接合部腺癌の治療薬として中国で承認しています。さらに、2020年5月には、米国FDAより、胃がんを対象としたエンヘルトゥのオーファンドラッグ指定がなされました。その後、2021年1月には、米国FDAがエンヘルトゥを進行性または転移性疾患の治療薬として承認しました。

ハーセプチンなどの主要薬剤の特許切れや、その後のバイオシミラーの発売は、胃がん治療市場の成長を抑制すると予想されます。さらに、高コストのため標的療法の採用が少ないことも、市場の成長を阻害する可能性があります。例えば、サイラムザは、他の薬剤と比較して費用対効果が低いと考えられていました。英国では費用対効果の低さを理由にNICEから却下されました。さらに、フランスでは、臨床的に適切な比較対象品と比較して追加的なメリットがないとして、償還が拒否されました。

胃がん治療市場レポートハイライト

標的療法治療タイプは、堅牢な臨床パイプラインと新製品の承認により、2021年に2番目に大きな売上シェアを占めました。例えば、2021年1月に米国FDAは、転移性または局所進行性のHER-2陽性胃がん患者の治療薬としてEnhertuを承認した

治療タイプ別では、オプジーボやキイトルーダなどのPD-1阻害剤の胃がん治療市場への投入・採用により、免疫療法が予測期間中に最も速い成長を見せると予想される

適応症別では、胃がん/胃食道接合部がんは有病率が高く、さまざまな製品があることから、予測期間中もリードを保つと予想されます。消化管間質腫瘍（GIST）セグメントは、製品上市数の増加により成長が期待される

流通チャネル別では、2021年の胃がん治療薬市場は専門薬局および小売薬局のセグメントが優勢でした。標的治療薬や免疫治療薬は、保管や物流の面で特別な要件があることが多いため、専門薬局で流通させることが多い

アジア太平洋地域は、同地域の高い疾病負担と研究イニシアティブにより、予測期間中も優位性を維持すると予想されます。Globocanのレポートによると、2020年の胃がん新規症例数の約75.3%がアジアで占められています。

欧州は、対象患者数の増加や標的治療薬・免疫治療薬の承認により、予測期間中に大幅な成長が見込まれています。

第1章調査手法と範囲

調査手法
調査の仮定
- 推定・予測のタイムライン
調査手法
情報調達
- 購入したデータベース
- GVRの内部データベース
- 二次情報
- 1次調査
- 1次調査内容
情報またはデータ分析
- データ分析モデル
市場の策定と検証
モデルの詳細
- コモディティフロー分析
  - アプローチ1：コモディティフローアプローチ
  - アプローチ2：ボトムアップアプローチを使用した国ごとの市場推定
世界市場：CAGR計算
二次情報一覧
一次情報のリスト
目的
テーブルのリスト

第2章エグゼクティブサマリー

市場概要
市場セグメンテーション

第3章市場変数、動向、範囲

浸透と成長の見通しのマッピング
規制の枠組み
胃がん治療市場力学
- 市場促進要因分析
  - 堅牢な製品パイプライン
  - 病気の有病率の増加
- 市場制約分析
  - 現在承認されている標的療法に対する償還の欠如
- 市場機会分析
PESTEL分析
ポーターのファイブフォース分析
主要な取引と戦略的提携の分析
- 新製品の発売
- 拡張
- パートナーシップ
- 協定
パイプライン分析
- 主要な今後の製品の分析
国別の疫学分析
アンメットニーズ

第4章治療型ビジネス分析（患者シェア %）

胃がん治療市場：治療タイプの変動分析
化学療法
免疫療法
標的療法
放射線治療と手術

第5章適応症ビジネス分析

胃がん治療市場：疾患適応症の変動分析
胃がん・食道胃接合部がん
消化管間質腫瘍

第6章医薬品クラスのビジネス分析（患者シェア%）

胃がん治療市場：薬物クラスの変動分析
PD-1/PD-L1阻害剤
HER2アンタゴニスト
VEGFR2拮抗薬
その他

第7章経営経路のビジネス分析

胃がん治療市場：投与経路の変動分析
オーラル
注射可能

第8章流通チャネルのビジネス分析

胃がん治療市場：流通経路の変動分析
病院薬局
専門店と小売店の薬局
その他

第9章地域推定・動向分析

地域市場のスナップショット
- 北米
  - 米国
  - カナダ
- 欧州
  - 英国
  - ドイツ
  - スペイン
  - フランス
  - イタリア
- アジア太平洋地域
  - 中国
  - 日本
  - インド
  - 韓国
  - オーストラリア
- ラテンアメリカ
  - ブラジル
  - メキシコ
  - アルゼンチン
- 中東とアフリカ
  - 南アフリカ
  - サウジアラビア
  - アラブ首長国連邦

第10章胃がん市場-競合分析

主要な市場参加者別最近の動向と影響分析
企業/競合の分類（主要なイノベーター、マーケットリーダー、新興企業）
公開会社
- 企業の市況分析（収益、地理的プレゼンス、製品ポートフォリオ、主要なサービス可能産業、主要な提携）
- 競合ダッシュボード分析
  - 市場の差別化要因
プライベートカンパニー
- 主要な新興企業の/テクノロジーディスラプター/イノベーターのリスト
- 地域ネットワークマップ
- 企業の市況分析（地理的プレゼンス、製品ポートフォリオ、主要な提携関係、業界経験）
企業プロファイル
- Eli Lilly and Company
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- F. Hoffmann-La Roche Ltd.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Pfizer Inc.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Novartis AG
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Merck &Co., Inc.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Samsung Bioepis
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Biocon
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Mylan NV
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Teva Pharmaceutical Industries Ltd.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Celltrion Healthcare Co., Ltd.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ

図表

List of Tables

TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Global Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (Patient Share in %, USD Million)
TABLE 4 Global Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (Patient Share in %, USD Million)
TABLE 5 Global Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 6 Global Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 7 Global Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 8 Global Stomach Cancer Treatment market, by Region, 2018 - 2030 (USD Million)
TABLE 9 North America Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
TABLE 10 North America Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 11 North America Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 12 North America Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 13 North America Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 14 North America Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 15 U.S. Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 16 U.S. Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 17 U.S. Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 18 U.S. Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 19 U.S. Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 20 Canada Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 21 Canada Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 22 Canada Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 23 Canada Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 24 Canada Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 25 Europe Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
TABLE 26 Europe Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 27 Europe Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 28 Europe Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 29 Europe Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 30 Europe Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 31 Germany Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 32 Germany Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 33 Germany Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 34 Germany Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 35 Germany Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 36 U.K. Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 37 U.K. Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 38 U.K. Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 39 U.K. Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 40 U.K. Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 41 France Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 42 France Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 43 France Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 44 France Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 45 France Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 46 Italy Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 47 Italy Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 48 Italy Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 49 Italy Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 50 Italy Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 51 Spain Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 52 Spain Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 53 Spain Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 54 Spain Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 55 Spain Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 56 Asia Pacific Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
TABLE 57 Asia Pacific Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 58 Asia Pacific Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 59 Asia Pacific Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 60 Asia Pacific Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 61 Asia Pacific Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 62 China Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 63 China Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 64 China Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 65 China Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 66 China Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 67 Japan Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 68 Japan Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 69 Japan Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 70 Japan Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 71 Japan Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 72 India Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 73 India Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 74 India Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 75 India Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 76 India Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 77 South Korea Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 78 South Korea Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 79 South Korea Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 80 South Korea Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 81 South Korea Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 82 Australia Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 83 Australia Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 84 Australia Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 85 Australia Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 86 Australia Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 87 Latin America Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
TABLE 88 Latin America Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 89 Latin America Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 90 Latin America Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 91 Latin America Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 92 Latin America Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 93 Brazil Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 94 Brazil Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 95 Brazil Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 96 Brazil Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 97 Brazil Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 98 Mexico Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 99 Mexico Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 100 Mexico Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 101 Mexico Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 102 Mexico Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 103 Argentina Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 104 Argentina Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 105 Argentina Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 106 Argentina Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 107 Argentina Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 108 Middle East & Africa Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
TABLE 109 Middle East & Africa Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 110 Middle East & Africa Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 111 Middle East & Africa Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 112 Middle East & Africa Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 113 Middle East & Africa Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 114 South Africa Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 115 South Africa Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 116 South Africa Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 117 South Africa Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 118 South Africa Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 119 Saudi Arabia Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 120 Saudi Arabia Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 121 Saudi Arabia Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 122 Saudi Arabia Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 123 Saudi Arabia Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
TABLE 124 UAE Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
TABLE 125 UAE Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
TABLE 126 UAE Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
TABLE 127 UAE Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
TABLE 128 UAE Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Epidemiology - based market sizing & Forecasting
FIG. 6 Market Formulation & Validation
FIG. 7 Stomach Cancer Treatment Market, Market Segmentation
FIG. 8 Market Snapshot, 2021
FIG. 9 Market Trends & Outlook
FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
FIG. 13 Porter's Five Forces Analysis
FIG. 14 Market Penetration Vs Growth Prospect Mapping, 2021
FIG. 15 Global Stomach Cancer Treatment Market:Treatment Type Movement Analysis
FIG. 16 Global Stomach Cancer Treatment Market, for Chemotherapy, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 17 Global Stomach Cancer Treatment Market, for Immunotherapy, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 18 Global Stomach Cancer Treatment Market, for Targeted drugs, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 19 Global Stomach Cancer Treatment Market: Disease Indication Movement Analysis
FIG. 20 Global Stomach Cancer Treatment Market, for Gastric Cancer/Gastroesophageal Junction Cancer, 2018 - 2030 (USD Million)
FIG. 21 Global Stomach Cancer Treatment Market, for Gastrointestinal Stromal Tumors, 2018 - 2030 (USD Million)
FIG. 22 Global Stomach Cancer Treatment Market: Route of Administration Movement Analysis
FIG. 23 Global Stomach Cancer Treatment Market, for Oral, 2018 - 2030 (USD Million)
FIG. 24 Global Stomach Cancer Treatment Market, for Injectable, 2018 - 2030 (USD Million)
FIG. 25 Global Stomach Cancer Treatment Market: Drug Class, Movement Analysis
FIG. 26 Global Stomach Cancer Treatment Market, for PD - 1/ PD - L1 inibitors, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 27 Global Stomach Cancer Treatment Market, for HER2 Antagonists, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 28 Global Stomach Cancer Treatment Market, for VEGFR Antagonists, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 29 Global Stomach Cancer Treatment Market, for Others, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 30 Global Stomach Cancer Treatment Market: Distribution Channel, Movement Analysis
FIG. 31 Global Stomach Cancer Treatment Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
FIG. 32 Global Stomach Cancer Treatment Market, for Specialty & Retail Pharmacies, 2018 - 2030 (USD Million)
FIG. 33 Global Stomach Cancer Treatment Market, for Others, 2018 - 2030 (USD Million)
FIG. 34 Regional Marketplace: Key Takeaways
FIG. 35 Regional Outlook, 2021 & 2030
FIG. 36 Global Stomach Cancer Treatment Market: Regional Movement Analysis
FIG. 37 North AmericaStomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 38 U.S. Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 39 Canada Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 40 Europe Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 41 Germany Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 42 U.K. Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 43 France Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 44 Italy Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 45 Spain Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 46 Asia Pacific Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 47 Japan Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 48 China Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 49 India Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 50 Australia Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 51 South Korea Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 52 Latin AmericaStomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 53 Brazil Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 54 Mexico Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 55 Argentina Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 56 Middle East and Africa Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 57 South Africa Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 58 Saudi Arabia Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 59 UAE Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)

Product Code: GVR-4-68039-973-9

Stomach Cancer Treatment Market Growth & Trends:

The global stomach cancer treatment market size is expected to reach USD 11.2 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 12.9% from 2022 to 2030. Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics' drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Stomach Cancer Treatment Market Report Highlights:

The targeted therapy treatment type segment held the second-largest revenue share in 2021 due to the robust clinical pipeline and approval of new products. For instance, in January 2021, the U.S. FDA approved Enhertu for the treatment of patients with metastatic or locally advanced HER-2 positive gastric cancers

By treatment type, immunotherapy is anticipated to witness the fastest growth during the forecast period due to the launch and adoption of PD-1 inhibitors such as Opdivo and Keytruda in the gastric cancer therapy market

By disease indication, the gastric cancer/gastroesophageal junction cancer segment is expected to maintain its lead during the forecast period due to the high prevalence of the disease and the availability of various products. The gastrointestinal stromal tumors (GISTs) segment is expected to grow due to the increasing number of product launches

Based on the distribution channel, the specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021. Targeted and immunotherapy drugs often have special requirements in terms of storage and logistics and are therefore distributed by specialty pharmacies

Asia Pacific is expected to maintain its dominance during the forecast period due to the high disease burden and research initiatives in the region. According to a Globocan report, Asia accounts for around 75.3% of all new cases of gastric cancer in 2020

Europe is anticipated to witness considerable growth during the forecast period owing to the increasing target patient population and approval of targeted and immunotherapy drugs

TABLE of Contents

Chapter 1 Methodology and Scope

1.1 Research Methodology
1.2 Research Assumptions
- 1.2.1 Estimates and Forecast Timeline
1.3 Research Methodology
1.4 Information Procurement
- 1.4.1 Purchased Database
- 1.4.2 GVR's Internal Database
- 1.4.3 Secondary Sources
- 1.4.4 Primary Research
- 1.4.5 Details of Primary Research
1.5 Information or Data Analysis
- 1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
- 1.7.1 Commodity Flow Analysis
  - 1.7.1.1 Approach 1: Commodity Flow Approach
  - 1.7.1.2 Approach 2: Country wise market estimation using bottom up approach
1.8 Global Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
- 1.11.1 Objective 1:
- 1.11.2 Objective 2:
1.12 List of TABLEs

Chapter 2 Executive Summary

2.1 Market Summary
2.2 Market Segmentation

Chapter 3 Market Variables, Trends & Scope

3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory framework
3.3 Stomach Cancer Treatment Market Dynamics
- 3.3.1 Market Driver Analysis
  - 3.3.1.1 Robust product pipeline
  - 3.3.1.2 Increasing prevalence of the disease
- 3.3.2 Market Restraint Analysis
  - 3.3.2.1 Lack of reimbursement for currently approved targeted therapies
- 3.3.3 Market Opportunity Analysis
3.4 PESTEL Analysis
3.5 Porter's Five Forces Analysis
3.6 Major deals and strategic alliances analysis
- 3.6.1 New product launch
- 3.6.2 Expansion
- 3.6.3 Partnership
- 3.6.4 Agreements
3.6 Pipeline Analysis
- 3.6.1 Analysis of key upcoming products
3.7 Epidemiology Analysis, by Country
3.8 Unmet Needs

Chapter 4 Treatment Type Business Analysis (Patient Share in %)

4.1 Stomach Cancer Treatment Market: Treatment Type Movement Analysis
4.2 Chemotherapy
- 4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030
4.3 Immunotherapy
- 4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030
4.4 Targeted Therapy
- 4.4.1 Targeted Therapy market estimates and forecast, 2018 - 2030
4.4 Radiation therapy & Surgery

Chapter 5 Disease Indication Business Analysis

5.1 Stomach Cancer Treatment Market: Disease Indication Movement Analysis
5.2 Gastric Cancer/Gastroesophageal Junction Cancer
- 5.2.1 Gastric Cancer/Gastroesophageal Junction Cancer market estimates and forecast, 2018 - 2030
5.3 Gastrointestinal Stromal Tumors
- 5.3.1 Gastrointestinal Stromal Tumors market estimates and forecast, 2018 - 2030

Chapter 6 Drug Class Business Analysis (Patient Share in %)

6.1 Stomach Cancer Treatment Market: Drug Class Movement Analysis
6.2 PD-1/PD-L1 inhibitors
- 6.2.1 PD-1/PD-L1 inhibitors market estimates and forecast, 2018 - 2030
6.3 HER2 antagonists
- 6.3.1 HER2 antagonists market estimates and forecast, 2018 - 2030
6.4 VEGFR2 antagonists
- 6.4.1 VEGFR2 antagonists market estimates and forecast, 2018 - 2030
6.5 Others
- 6.5.1 Others market estimates and forecast, 2018 - 2030

Chapter 7 Route of Administration Business Analysis

7.1 Stomach Cancer Treatment Market: Route of Administration Movement Analysis
7.2 Oral
- 7.2.1 Oral market estimates and forecast, 2018 - 2030
7.3 Injectable
- 7.3.1 Injectable market estimates and forecast, 2018 - 2030

Chapter 8 Distribution Channel Business Analysis

8.1 Stomach Cancer Treatment Market: Distribution Channel Movement Analysis
8.2 Hospital Pharmacies
- 8.2.1 Hospital Pharmacies market estimates and forecast, 2018 - 2030
8.3 Specialty & Retail Pharmacies
- 8.3.1 Specialty & Retail Pharmacies market estimates and forecast, 2018 - 2030
8.4 Others
- 8.4.1 Others market estimates and forecast, 2018 - 2030

Chapter 9 Regional Estimates & Trend Analysis

9.1. Regional Market Snapshot
- 9.1.1. North America
  - 9.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.1.2. U.S.
  - 9.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.1.3. Canada
  - 9.1.1.3.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
- 9.1.2. Europe
  - 9.1.2.1. Europe market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.2.2. U.K.
  - 9.1.2.2.1. U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.2.3. Germany
  - 9.1.2.3.1. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.2.4. Spain
  - 9.1.2.4.1. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.2.5. France
  - 9.1.2.5.1. France market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.2.9. Italy
  - 9.1.2.9.1. Italy market estimates and forecast, 2018 - 2030 (USD Million)
- 9.1.3. Asia Pacific
  - 9.1.3.1.Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.3.2. China
  - 9.1.3.2.1. China market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.3.3. Japan
  - 9.1.3.3.1. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.3.4. India
  - 9.1.3.4.1. India market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.3.5. South Korea
  - 9.1.3.5.1. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.3.9. Australia
  - 9.1.3.9.1. Australia market estimates and forecast, 2018 - 2030 (USD Million)
- 9.1.4. Latin America
- 9.1.4. Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.4.1. Brazil
  - 9.1.4.1.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.4.2. Mexico
  - 9.1.4.2.1. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.4.3. Argentina
  - 9.1.4.3.1. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
- 9.1.5. Middle East & Africa
  - 9.1.5.1. MEA market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.5.2. South Africa
  - 9.1.5.2.1. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.5.3. Saudi Arabia
  - 9.1.5.3.1. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  - 9.1.5.4. UAE
  - 9.1.5.4.1. UAE market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 10 Stomach Cancer Market - Competitive Analysis

10.1. Recent developments & impact analysis, by key market participants
10.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
10.3. Public Companies
- 10.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
- 10.3.2. Competitive Dashboard Analysis
  - 10.3.2.1. Market Differentiators
10.4. Private Companies
- 10.4.1. List of key emerging companies' /technology disruptors/innovators
- 10.4.2. Regional network map
- 10.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
10.5. Company Profiles
- 10.5.1. Eli Lilly and Company
  - 10.5.1.1. Company Overview
  - 10.5.1.2. Financial Performance
  - 10.5.1.3. Product Benchmarking
  - 10.5.1.4. Strategic Initiatives
- 10.5.2. F. Hoffmann-La Roche Ltd.
  - 10.5.2.1. Company Overview
  - 10.5.2.2. Financial Performance
  - 10.5.2.3. Product Benchmarking
  - 10.5.2.4. Strategic Initiatives
- 10.5.3. Pfizer Inc.
  - 10.5.3.1. Company Overview
  - 10.5.3.2. Financial Performance
  - 10.5.3.3. Product Benchmarking
  - 10.5.3.4. Strategic Initiatives
- 10.5.4. Novartis AG
  - 10.5.4.1. Company Overview
  - 10.5.4.2. Financial Performance
  - 10.5.4.3. Product Benchmarking
  - 10.5.4.4. Strategic Initiatives
- 10.5.5. Merck & Co., Inc.
  - 10.5.5.1. Company Overview
  - 10.5.5.2. Financial Performance
  - 10.5.5.3. Product Benchmarking
  - 10.5.5.4. Strategic Initiatives
- 10.5.6. Samsung Bioepis
  - 10.5.6.1. Company Overview
  - 10.5.6.2. Financial Performance
  - 10.5.6.3. Product Benchmarking
  - 10.5.6.4. Strategic Initiatives
- 10.5.10. Biocon
  - 10.5.10.1. Company Overview
  - 10.5.10.2. Financial Performance
  - 10.5.10.3. Product Benchmarking
  - 10.5.10.4. Strategic Initiatives
- 10.5.8. Mylan N.V.
  - 10.5.8.1. Company Overview
  - 10.5.8.2. Financial Performance
  - 10.5.8.3. Product Benchmarking
  - 10.5.8.4. Strategic Initiatives
- 10.5.9. Teva Pharmaceutical Industries Ltd.
  - 10.5.9.1. Company Overview
  - 10.5.9.2. Financial Performance
  - 10.5.9.3. Product Benchmarking
  - 10.5.9.4. Strategic Initiatives
- 10.5.10. Celltrion Healthcare Co., Ltd.
  - 10.5.10.1. Company Overview
  - 10.5.10.2. Financial Performance
  - 10.5.10.3. Product Benchmarking
  - 10.5.10.4. Strategic Initiatives